[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
March 22/29, 2016

Clinical GenomicsFrom Pathogenicity Claims to Quantitative Risk Estimates

Author Affiliations
  • 1Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts
  • 2Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, California
  • 3Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California
JAMA. 2016;315(12):1233-1234. doi:10.1001/jama.2016.1519

Fifteen years after the Human Genome Project, genomic variants have been associated with disease risk and outcomes in thousands of publications. Based largely on this literature, physicians who order genetic testing receive reports that indicate whether “pathogenic” variants have been found. This information aspires to form the basis of precision medicine. Knowledge of pathogenic variants is expected to lead to optimal management of individuals as well as their families through recommendations about further screening, prevention, and tailored treatment. However, in this Viewpoint, we suggest that current information on pathogenic variants is typically impossible to act on. This information is often unreliable and generally does not provide a quantitative measure of risk. The information the physician usually needs is the likelihood of disease among patients with the variant (penetrance), and an assessment of whether the genetic profile requires action or not.

First Page Preview View Large
First page PDF preview
First page PDF preview
×